Primary aldosteronism
Conditions
Interventions
once a day finerenone orally administered for 12 weeks
Sponsors
Wada Jun
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients aged 18 to 80 years old 2) Patients who provide written consent to participate in this study 3) Patients diagnosed with primary aldosteronism based on the results of at least one of the following tests: captopril challenge test or saline loading test
Exclusion criteria
Exclusion criteria: 1) Pregnant women 2) Breastfeeding women 3) Patients with severe renal dysfunction (eGFR: less than 25 mL/min/1.73m2) 4) Patients undergoing renal replacement therapy (hemodialysis or peritoneal dialysis) 5) Patients who have previously undergone renal transplantation 6) Patients with severe hepatic impairment (Child-Pugh classification B or C) 7) Patients with hyperkalemia (K > 5.5 mEq/L) 8) Patients with Addison's disease 9) Patients with a history of hypersensitivity to finerenone ingredients 10) Patients who have taken spironolactone, eplerenone, or esaxerenone within 8 weeks before enrollment 11) Patients taking drugs listed as contraindications for concomitant use for finerenone 12) Patients judged by the principal investigator or subinvestigator to be ineligible for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma renin activity after 4 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Active renin concentration after 4 and 12 weeks 2) Serum potassium level after 4 and 12 weeks 3) Proteinuria after 4 and 12 weeks 4) Albuminuria after 4 and 12 weeks 5) eGFR after 4 and 12 weeks 6) Clinic blood pressure after 4 and 12 weeks 7) Home blood pressure after 4 and 12 weeks 8) Incidence of hyperkalemia for 12 weeks 9) Incidence of doubling of serum creatinine for 12 weeks 10) Incidence of other adverse events for 12 weeks | — |
Contacts
Public ContactSatoshi Fujisawa
Okayama University Hospital
Outcome results
None listed